Victoria Sharp

Victoria Sharp

Auto-generated profile, based on publicly available information

Victoria Sharp

St. Luke's-Roosevelt Hospital Center Center for Comprehensive Care New York, NY United States

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2016 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AKAnn E Kurth
Ann E Kurth
NCNok Chhun
Nok Chhun
CCCharles M Cleland
Charles M Cleland
MCMichele Crespo-Fierro
Michele Crespo-Fierro
JPJosé A Parés-Avila
José A Parés-Avila
VSVictoria L Sharp
Victoria L Sharp
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

5 October 2011 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Nafis RahmanNafis Rahman
Nafis Rahman
Herjan J.T. Coelingh BenninkHerjan J.T. Coelingh Bennink
Herjan J.T. Coelingh Bennink
MCMarcin Chrusciel
Marcin Chrusciel
VSVictoria Sharp
Victoria Sharp
YZYvette Zimmerman
Yvette Zimmerman
IHIlpo Huhtaniemi
Ilpo Huhtaniemi
We tested the principle of treating malignant ovarian tumors by vaccination against their ectopically expressed protein, zona pellucida glycoprotein (ZP) 3, using as the experimental model the granulosa cell tumors that develop in transgenic mice expressing the simian virus 40 T‐antigen under the inhibin‐α promoter (inhα/Tag). We found high ZP3 expression in granulosa cell tumors of the transgenic mice, in human surface ovarian cancer and granulosa cell lines, and in human granulosa cell tumors and their metastases. Early preventive immunization (between 2 and 5.5 mo of age) of transgenic mice with recombinant human (rh) ZP3 prevented ovarian tumorigenesis, and delayed therapeutic immunization (between 4.5 and 7 mo) reduced weights of existing tumors by 86 and 75%, respectively ( P <0.001), compared to vehicle‐treated control mice. No objective side effects of the immunizations were observed. Liver metastases were found in nontreated/vehicle‐treated controls ( n =7/39), but none following active rhZP3 immunizations ( n =0/36; P <0.05). Immunization with rhZP3 was highly effective, as demonstrated by the induction of anti‐ZP3 antibodies, as well as proliferative responses to the ZP3 antigen. These results signal rhZP3 immunization as a novel strategy to be developed for the immunotherapy of ovarian granulosa cell tumors, as well as for that of other malignancies that may express ZP3.Rahman, N. A., Coelingh Bennink, H.J. T., Chrusciel, M., Sharp, V., Zimmerman, Y., Dina, R., Li, X., Ellonen, A., Rivero‐Müller, A., Dilworth, S., Ghaem‐Maghami, S., Vainio, O., Huhtaniemi, I. A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3. FASEB J. 26, 324–333 (2012). www.fasebj.org

17 February 2014 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
JNJolene H Nakao
Jolene H Nakao
DWDan E Wiener
Dan E Wiener
DNDavid H Newman
David H Newman
VSVictoria L Sharp
Victoria L Sharp
DEDaniel J Egan
Daniel J Egan
Summary Newly diagnosed HIV-positive patients have frequent health care encounters prior to diagnosis representing missed opportunities for diagnosis. This study determines the proportion of patients with new HIV diagnoses with encounters in the 3 years prior to diagnosis. We describe the characteristics of newly diagnosed patients and of “late testers” (CD4 <200 cells/mm3 at the time of diagnosis). We identified all newly diagnosed with HIV in emergency department, inpatient, and outpatient settings between May 1, 2006, and December 31, 2009. Data abstractors searched hospital records to identify all emergency department, inpatient, and outpatient visits for the 3 years prior to diagnosis. In all, 23,271 HIV tests were performed and 253 persons were newly diagnosed (1.1%); 152 new positives (60.1%) made at least one prior visit. Of patients with CD4 counts available, 104/175 (59.4%) had CD4 <200 cells/mm3. Patients with at least one prior visit had a median of three. There was no difference in numbers of visits between late testers and non-late testers, although late testers were more likely to have ED visits. Most newly diagnosed HIV-positive patients had multiple encounters prior to diagnosis. Many of these patients presented with CD4 counts below 200 cells/mm3, indicating true missed opportunities for earlier diagnosis.